Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.49 |
| ▸ | HRH2 | P25021 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29165086 | 1.00 | HSD17B10 (0.49) | HSD17B10UCHL1HRH2HRH1L3MBTL3 | |
| SCHEMBL27145826 | 1.00 | HSD17B10 (0.49) | HSD17B10UCHL1HRH2HRH1L3MBTL3 | |
| SCHEMBL30019310 | 0.95 | HRH2 (0.45) | HSD17B10UCHL1HRH2HRH1L3MBTL3 | |
| Hydrochloric Acid SCHEMBL30019151 | 0.91 | HRH2 (0.42) | HSD17B10UCHL1HRH2HRH1RXFP1 | |
| SCHEMBL27142178 | 0.86 | USP2 (0.51) | L3MBTL3L3MBTL1MAPT | |
| SCHEMBL29165129 | 0.86 | USP2 (0.51) | L3MBTL3L3MBTL1MAPT | |
| SCHEMBL3274885 | 0.81 | HSD17B10 (0.71) | HSD17B10UCHL1HRH2HRH1 | |
| SCHEMBL13779912 | 0.81 | HSD17B10 (0.71) | HSD17B10UCHL1HRH2HRH1 | |
| SCHEMBL6973694 | 0.81 | HSD17B10 (0.71) | HSD17B10UCHL1HRH2HRH1 | |
| SCHEMBL14494457 | 0.79 | RIPK1 (0.47) | UCHL1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ADORA2A, ADORA1, ADORA2B | HSD17B10 2827/4885UCHL1 4251/4885HRH2 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.